Registration of securities issued in business combination transactions

Recent Developments, Liquidity and Management's Plans (Details Narrative)

v3.20.4
Recent Developments, Liquidity and Management's Plans (Details Narrative)
1 Months Ended 12 Months Ended
Feb. 25, 2021
USD ($)
Jan. 21, 2021
USD ($)
Nov. 17, 2020
USD ($)
$ / shares
shares
Nov. 12, 2020
Integer
Nov. 11, 2020
USD ($)
$ / shares
shares
Nov. 11, 2020
USD ($)
$ / shares
shares
Oct. 31, 2020
USD ($)
$ / shares
shares
Oct. 13, 2020
USD ($)
Aug. 13, 2020
USD ($)
May 18, 2020
USD ($)
May 14, 2020
Apr. 20, 2020
USD ($)
Apr. 10, 2020
USD ($)
Apr. 08, 2020
USD ($)
$ / shares
shares
Mar. 24, 2020
USD ($)
shares
Mar. 23, 2020
USD ($)
Feb. 23, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Research and development expenses                                   $ 7,963,678  
Total Liabilities                                   2,263,295 1,529,765  
Trade and Other Payables                                   $ 2,203,902 891,883  
Ownership percentage                                   20.00%    
Cash                                   $ 18,617,955 517,444  
Marketable securities                                   16,718,452    
Net loss                                   (17,580,609) (3,888,249)  
Working capital                                   34,579,466    
Net cash used in operating activities                                   (11,924,941) (3,074,283)  
Net loss from continuing operations                                   (12,152,214) (3,381,295)  
Net loss from discontinuing operations                                   (5,428,395) (506,954)  
Total Shareholders' Equity                                   34,579,466 9,355,170 $ 5,833,753
Accumulated deficit                                   (137,163,739) (119,583,130)  
Trading days | Integer       10                                
Deposits and Other Receivables                                   1,200,009  
Proceeds from common stock                                   29,184,244 2,147,778  
Net proceeds from issuance of pre-funded warrants for the purchase of common stock                                   1,743,503 4,817,857  
Private Placement [Member]                                        
Share price | $ / shares     $ 1.85                                  
Stock issued during the period | shares     8,725,393                                  
Proceeds from common stock     $ 16,362,786                                  
Warrants exercise price | $ / shares     $ 1.85                                  
Net proceeds from issuance of pre-funded warrants for the purchase of common stock                                 $ 932,432      
Holder [Member] | Private Placement [Member]                                        
Warrants description           A holder (together with its affiliates) may not exercise any portion of the Investor Warrant to the extent that the holder would own more than 4.99% (or, at the election of the holder prior to the date of issuance, 9.99%) of the outstanding Akers common stock immediately after exercise; provided, however that upon notice to Akers, the holder may increase or decrease the beneficial ownership limitation, provided that in no event shall the beneficial ownership limitation exceed 9.99%                            
Former Members [Member] | Private Placement [Member]                                        
Proceeds from issuance of private placement     $ 1,204,525                                  
Minimum [Member]                                        
Share price | $ / shares         $ 5.00 $ 5.00                            
Premas Biotech PVT Ltd [Member]                                        
Trade and Other Payables                                   1,510,290    
Phase I Clinical Trial [Member]                                        
Contingent payments upon achievement of certain milestones                                   250,000    
Phase II Clinical Trial [Member]                                        
Contingent payments upon achievement of certain milestones                                   500,000    
Phase III Clinical Trial [Member]                                        
Contingent payments upon achievement of certain milestones                                   5,000,000    
COVID-19 Vaccine [Member]                                        
Contingent payments upon achievement of certain milestones                                   15,000,000    
Royalty payments, description                               The Company shall also make quarterly royalty payments to Sellers equal to 5% of the net sales of a COVID-19 vaccine or combination product by the Company (the "COVID-19 Vaccine") for a period of five (5) years following the first commercial sale of the COVID-19 Vaccine; provided, that such payment shall be reduced to 3% for any net sales of the COVID-19 Vaccine above $500 million.        
Pre-Funded Warrants [Member] | Private Placement [Member]                                        
Stock issued during the period | shares         9,765,933                              
Warrants exercise price | $ / shares         $ 0.01 $ 0.01                            
Investor Warrants [Member] | Private Placement [Member]                                        
Stock issued during the period | shares           9,765,933                            
Warrants exercise price | $ / shares     $ 2.06   $ 2.06 $ 2.06                            
Common Stock [Member]                                        
Net loss                                    
Total Shareholders' Equity                                   171,598,681 128,920,414 $ 121,554,547
Stock issued during the period | shares     8,725,393                                  
Proceeds from common stock     $ 18,066,976                                  
Shares issued price per share | $ / shares     $ 1.85                                  
Series D Convertible Preferred Stock [Member]                                        
Total Shareholders' Equity                                      
Katalyst Securities LLC [Member]                                        
Warrants exercise price | $ / shares             $ 1.85                          
Equal fee percent             6.50%                          
Proceeds from issuance of private placement             $ 25,000                          
Katalyst Securities LLC [Member] | Maximum [Member]                                        
Purchase of warrants | shares             390,368                          
Membership Interest Purchase Agreement [Member]                                        
Research and development expenses                                   5,867,046    
Payment to sellers     $ 1,204,525                         $ 1,000,000        
Proceeds from initial equity offering                               $ 8,000,000        
Percentage of payment to sellers on equity offering                               10.00%        
Additional cash consideration                               $ 10,000,000        
Achievement of milestone, description                               Upon the achievement of certain milestones, including the completion of a Phase 2 study for a COVID-19 vaccine that meets its primary endpoints, Sellers will be entitled to receive an additional 750,000 shares of our common stock or, in the event we are unable to obtain stockholder approval for the issuance of such shares, 750,000 shares of non-voting preferred stock that are valued following the achievement of such milestones and shall bear a 10% annual dividend (the "Milestone Shares").        
Contingent payments upon achievement of certain milestones                       $ 250,000                
Total Liabilities     602,172                                  
Royalty payments to sellers, percentage                               0.125        
Membership Interest Purchase Agreement [Member] | Cystron and Premas [Member]                                        
Purchase of initial cash component               $ 908,117                        
Membership Interest Purchase Agreement [Member] | Cystron [Member]                                        
Ownership percentage               100.00%                        
Membership Interest Purchase Agreement [Member] | Premas Biotech PVT Ltd [Member]                                        
Achievement of milestone, description                     The Company and Premas agreed that the fourth milestone under the License Agreement had been satisfied. Due to the achievement of this milestone on July 7, 2020, Premas was paid $1,000,000 on August 4, 2020. Accordingly, for the year ended December 31, 2020, Research and Development Expenses of $2,000,000 were recorded in the Consolidated Statements of Comprehensive Loss.                  
Membership Interest Purchase Agreement [Member] | May Payment [Member]                                        
Payment to sellers upon consummation direct equity offering                   $ 892,500                    
Membership Interest Purchase Agreement [Member] | August Payment [Member]                                        
Payment to sellers upon consummation direct equity offering                 $ 684,790                      
Membership Interest Purchase Agreement [Member] | Cystron Biotech, LLC [Member]                                        
Agreement description                               As consideration for the Membership Interests (as defined in the MIPA), the Company delivered to the members of Cystron (the "Sellers"): (1) that number of newly issued shares of its common stock equal to 19.9% of the issued and outstanding shares of its common stock and pre-funded warrants as of the date of the MIPA, but, to the extent that the issuance of its common stock would have resulted in any Seller owning in excess of 4.9% of the Company's outstanding common stock, then, at such Seller's election, such Seller received "common stock equivalent" preferred shares with a customary 4.9% blocker (with such common stock and preferred stock collectively referred to as "Common Stock Consideration"), and (2) $1,000,000 in cash. On March 24, 2020 the Company paid $1,000,000 to the Sellers and delivered 411,403 shares of common stock and 211,353 shares of Series D Convertible Preferred Stock with a customary 4.9% blocker, with an aggregate fair market value of $1,233,057, and recorded $2,233,057 ("March Transaction").        
Proceeds from collaborators                               $ 1,000,000        
Payment to the sellers                             $ 1,000,000          
Membership Interest Purchase Agreement [Member] | Cystron Biotech, LLC [Member] | Premas Biotech PVT Ltd [Member]                                        
Achievement of milestone, description                               Upon the achievement of certain developmental milestones by Cystron, Cystron shall pay to Premas a total of up to $2,000,000. On April 16, 2020, the Company paid Premas $500,000 for the achievement of the first two development milestones. On May 18, 2020, the Company paid Premas $500,000 for the achievement of the third development milestone.        
Membership Interest Purchase Agreement [Member] | Cystron Biotech, LLC [Member] | Common Stock [Member]                                        
Number of shares delivered | shares                             411,403          
Fair market value shares delivered                             $ 1,233,057          
Research and development expenses                             $ 2,233,057          
Membership Interest Purchase Agreement [Member] | Cystron Biotech, LLC [Member] | Series D Convertible Preferred Stock [Member]                                        
Number of shares delivered | shares                             211,353          
Percentage of blocker                             4.90%          
Fair market value shares delivered                             $ 1,233,057          
Research and development expenses                             $ 2,233,057          
License Agreement [Member]                                        
Research and development expenses                                   2,000,000    
Cystron Medical Panel [Member]                                        
Research and development expenses                                   31,573    
Achievement of milestone, description                         The Cystron Medical Panel and appointed its first member to the panel. Each member shall be compensated with an initial grant of the Company's common stock with an aggregate fair market value of $25,000 and a monthly cash stipend in the initial amount of $2,500              
Fair market value common stock                         $ 25,000              
Monthly cash stipend in initial amount                         $ 2,500              
Merger Agreement [Member] | Minimum [Member] | Private Placement [Member]                                        
Cash     $ 25,000,000                                  
Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member]                                        
Ownership percentage         80.00% 80.00%                            
Stock issued during the period | shares           300,000                            
Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member] | Secured Promissory Note [Member]                                        
Debt instrument, maturity date           Apr. 15, 2022                            
Deposits and Other Receivables                                   $ 1,200,000    
Proceeds from issuance of debt $ 1,200,000 $ 600,000                                    
Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member] | Extended Maturity [Member]                                        
Debt instrument, maturity date description           The Merger Agreement contains certain termination rights for both the Company and MYMD, including, among other things, (a) Akers may, upon written notice, extend the originally scheduled End Date (defined in the Merger Agreement as April 15, 2021) to May 15, 2021 (the "Extended Date") so long as (i) Akers and Merger Sub are not then in material breach of any provision of the Merger Agreement and (ii) within three calendar days of the written request by MYMD, Akers makes an additional loan to MYMD of up to $600,000, which will have the same terms and conditions of the Note (as defined below and such additional note "Second Note") and (b) Akers may, upon written notice, extend the Extended Date to June 30, 2021, so long as (i) Akers and Merger Sub are not then in material breach of any provision of the Merger Agreement, (ii) on the effective date of such extension, the loan amount evidenced by the Note and the Second Note may, at the sole option of MYMD upon written notice to Akers, be converted into shares of MYMD common stock at a conversion price of $2.00 per share, subject to certain adjustments and (iii) Akers will, at MYMD's request, either (at the option of MYMD); (A) subscribe for 300,000 shares of MYMD common stock at a subscription price of $2.00 per share, subject to certain adjustments as set forth in the Merger Agreement, or (B) makes an additional loan to MYMD of up to $600,000, which will have the same terms and conditions of the Note (the "Third Note," and all amounts outstanding under the Note, the Second Note and the Third Note, the "Loan Amount"). In addition, if Akers terminates the Merger Agreement under certain circumstances specified therein, the Loan Amount, if any, at the sole discretion of MYMD, will be convertible into shares of common stock of MYMD at a conversion price of $2.00 per share upon delivery of written notice by MYMD to Akers within 30 calendar days after the effective date of termination of the Merger Agreement.                            
Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member] | Maximum [Member]                                        
Loans payable         $ 3,000,000 $ 3,000,000                            
Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member] | Maximum [Member] | Second Note [Member]                                        
Loans payable         600,000 600,000                            
Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member] | Maximum [Member] | Third Note [Member]                                        
Loans payable         $ 600,000 $ 600,000                            
Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member] | Maximum [Member] | Secured Promissory Note [Member]                                        
Conversion price, per share | $ / shares         $ 2.00 $ 2.00                            
Loans payable         $ 3,000,000 $ 3,000,000                            
Debt instrument, interest rate         5.00% 5.00%                            
Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member] | Minimum [Member]                                        
Share price | $ / shares         $ 5.00 $ 5.00                            
Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member] | Post-Closing Shares [Member]                                        
Ownership percentage         20.00% 20.00%                            
Securities Purchase Agreement [Member] | Accredited Investors [Member]                                        
Share price | $ / shares         $ 1.85 $ 1.85               $ 6.00            
Stock issued during the period | shares           9,765,933               766,667            
Proceeds from common stock           $ 18,100,000               $ 4,086,207            
Prepaid Equity Forward Contracts [Member]                                        
Stock issued during the period | shares     1,040,540                                  
Proceeds from common stock     $ 16,362,786